| Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co.'s products and services enable the adoption of genomic solutions in research and clinical settings. Co.'s principal products, services, and technologies are: sequencing, which includes Deoxyribonucleic acid (DNA) sequencing, a process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample; arrays, which are used for a range of DNA and RNA analysis applications; consumables, which Co. has developed various library preparation and sequencing kits; and services, which provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. We show 53 historical shares outstanding datapoints in our ILMN shares outstanding history coverage, used to compute ILMN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ILMN market cap history over the course of time is important for investors
interested in comparing ILMN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ILMN versus a peer is one thing; comparing
ILMN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ILMN can fluctuate over the course of history.
With this page we aim to empower investors researching ILMN by allowing them to research the ILMN market cap history.